Aldinc, Emre
Campbell, Courtney
Gustafsson, Finn
Beveridge, Abigail
Macey, Richard
Marr, Laura
Summers, Catherine
Zhang, Dafang
Funding for this research was provided by:
Alnylam Pharmaceuticals
Article History
Received: 27 April 2023
Accepted: 4 September 2023
First Online: 22 September 2023
Declarations
:
: Not applicable this is a secondary analysis of primary research.
: Not applicable this is a secondary analysis of primary research.
: Catherine Summers and Emre Aldinc are employees of Alnylam Pharmaceuticals. Finn Gustafsson is an adviser to Alnylam, Ionis and Pfizer. Courtney Campbell is an adviser to Alnylam and Pfizer and has received research support from Alnylam and Akari Therapeutics. Richard Macey, Abigail Beveridge, and Laura Marr are employees of Adelphi Values PROVE™. Adelphi Values PROVE™ received funding from Alnylam Pharmaceuticals for the conduct of the review, from development of the systematic review methodology through to overseeing the final formatting and manuscript submission processes.